Stock Rich List
#521 on the rich list of 14,644 insiders

Keith Manchester

Director at Roivant Sciences; Director at Arbutus Biopharma.

$447M
in disclosed stock, +$5.3M (+1.20%) today
Live prices, last trade 2:32 PM ET
Rank
521st of 14,644
Companies held
2
Largest holding
ROIV, 100.0% of total
Latest SEC filing
Nov 17, 2026

What the $447M is made of

Holdings counted

All filings on SEC.gov
CompanyHow heldSharesPriceValueShare of totalReported
Roivant Sciences ROIV
Common Shares
Held by QVT Financial Investment Cayman Ltd.
Reported jointly by 2 insiders; split evenly
6,749,547$39.20$265M59.2%Form 4, Nov 17, 2026
Roivant Sciences ROIV
Common Shares
Held by QVT Deferred Compensation Holdings Ltd.
Reported jointly by 2 insiders; split evenly
2,902,731$39.20$114M25.4%Form 4, Nov 17, 2026
Roivant Sciences ROIV
Common Shares
Directly1,753,457$39.20$68.7M15.4%Form 4, Sep 16, 2026
Arbutus Biopharma ABUS
Common Shares
Directly46,069$4.14$190K0.0%Form 4, Aug 14, 2024

Share counts are the amounts Keith Manchester reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.

Open-market trades, last 12 months

DateTradeCompanySharesPriceValueFiling
Nov 17, 2026SoldROIV75,716$38.24$2.9MView
Nov 17, 2026SoldROIV525,507$38.24$20.1MView
Nov 17, 2026SoldROIV798$38.24$31KView
Nov 16, 2026SoldROIV79,461$39.17$3.1MView
Nov 16, 2026SoldROIV550,280$39.17$21.6MView
Nov 16, 2026SoldROIV18,927$38.99$738KView
Nov 16, 2026SoldROIV131,073$38.99$5.1MView
Jun 30, 2026SoldROIV200,000$35.45$7.1MView
Jun 30, 2026SoldROIV12,380$35.28$437KView
Jun 29, 2026SoldROIV600,000$34.59$20.8MView
Jun 29, 2026SoldROIV200,000$34.44$6.9MView
Jun 26, 2026SoldROIV325,000$34.07$11.1MView
Jun 26, 2026SoldROIV300,783$33.92$10.2MView
Feb 13, 2026SoldROIV150,784$26.49$4.0MView
Feb 13, 2026SoldROIV225,000$26.50$6.0MView
Feb 12, 2026SoldROIV275,000$26.76$7.4MView
Feb 12, 2026SoldROIV150,000$26.72$4.0MView
Feb 11, 2026SoldROIV425,000$26.67$11.3MView
Dec 17, 2025SoldROIV189,538$23.17$4.4MView
Dec 17, 2025SoldROIV432,718$23.05$10.0MView
Dec 17, 2025SoldROIV155,076$23.02$3.6MView
Dec 16, 2025SoldROIV275,000$22.93$6.3MView
Dec 16, 2025SoldROIV642,282$23.08$14.8MView
Nov 19, 2025SoldROIV850,000$20.25$17.2MView
Nov 19, 2025SoldROIV150,000$20.20$3.0MView

Nearby on the list

Full list
Nearby ranks
RankNameStock holdingsToday
518Lawrence James Lawson III
Director, Lincoln International. Chicago, IL
$450M−$8.8M (−1.92%)
519Noubar B. Afeyan
Director, Moderna. Cambridge, MA
$447M+$9.0M (+2.06%)
520Dean Solon
10% owner, Shoals Technologies Group. Portland, TN
$447M+$17.1M (+3.98%)
521Keith Manchester
Director, Roivant Sciences
$447M+$5.3M (+1.20%)
522Raul Marcelo Claure
Director, T-Mobile US. Bellevue, WA
$446M−$3.8M (−0.85%)
523Michael Ho
Chief Strategy Officer, Hut 8. Miami, FL
$445M−$3.2M (−0.71%)
524Yair Nechmad
CEO, Co Founder & Chairman, Nayax
$445M−$9.6M (−2.10%)

Other Roivant Sciences insiders

All ROIV insiders

Questions

How much stock does Keith Manchester own?

Keith Manchester holds $447,238,239 in listed stock based on SEC filings and current prices, mostly Roivant Sciences (ROIV). That ranks 521st on the Stock Rich List.

Is this Keith Manchester's net worth?

No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.

When did Keith Manchester last buy or sell stock?

The most recent open-market trade on file is a sale of 75,716 ROIV shares on Nov 17, 2026 at $38.24.